Cite
MLA Citation
A. Sharp et al.. “PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL.” HemaSphere, vol. 6, n.d., pp. 1970–1971. http://access.bl.uk/ark:/81055/vdc_100158013756.0x00002e